Inventor · disambiguated record
Janne Juha Turunen
Also filed as: TURUNEN JANNE JUHA
13 granted patents·8 pending applications·66 citations·filing 2016–2024
90Inventor score
Top patents by PatentIndex Score
21 records- 0193US11851656B2Chemically modified single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2021·Granted Dec 26, 2023·6 cites·40 claims
- 0293US10941402B2Chemically modified single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2017·Granted Mar 9, 2021·16 cites·22 claims
- 0391US12203072B2Chemically modified single-stranded rna-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2023·Granted Jan 21, 2025·1 cites·29 claims
- 0491US12018257B2Single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2023·Granted Jun 25, 2024·2 cites·13 claims
- 0591US11274300B2Oligonucleotide complexes for use in RNA editingPROQR THERAPEUTICS II BV·Filed 2018·Granted Mar 15, 2022·17 cites·20 claims
- 0690US11649454B2Single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2021·Granted May 16, 2023·4 cites·41 claims
- 0788US10988763B2Single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2017·Granted Apr 27, 2021·13 cites·20 claims
- 0885US2025223593A1Chemically modified single-stranded rna-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2024·Application pending·0 cites
- 0984US10760076B2Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansionPROQR THERAPEUTICS II BV·Filed 2016·Granted Sep 1, 2020·2 cites·6 claims
- 1083US10617707B2Oligonucleotides to treat eye diseasePROQR THERAPEUTICS II BV·Filed 2017·Granted Apr 14, 2020·2 cites·15 claims
- 1182US10612025B2Antisense oligonucleotides for the treatment of eye diseasePROQR THERAPEUTICS II BV·Filed 2017·Granted Apr 7, 2020·2 cites·11 claims
- 1280US11123360B2Oligonucleotides to treat eye diseasePROQR THERAPEUTICS II BV·Filed 2020·Granted Sep 21, 2021·1 cites·17 claims
- 1368US2021401871A1Oligonucleotides to treat eye diseasePROQR THERAPEUTICS II BV·Filed 2021·Application pending·0 cites
- 1468US2024229030A9Nucleic acid molecules for pseudouridylationUNIV ROCHESTER·Filed 2023·Application pending·0 cites
- 1564US11479771B2Antisense oligonucleotides for the treatment of eye diseasePROQR THERAPEUTICS II BV·Filed 2020·Granted Oct 25, 2022·0 cites·16 claims
- 1662US11866702B2Nucleic acid molecules for pseudouridylationUNIV ROCHESTER·Filed 2019·Granted Jan 9, 2024·0 cites·24 claims
- 1759US2020362348A1Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansionPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 1852US2023235322A1Rna editing inhibitors and methods of usePROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 1951US2022307023A1Antisense rna editing oligonucleotides comprising cytidine analogsPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 2051US2022340900A1Chemically modified oligonucleotides for rna editingPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 2146US2021079393A1Antisense oligonucleotides for rna editingPROQR THERAPEUTICS II BV·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Janne Juha Turunen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →